NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,685,364 | +42.0% | 128,671 | -46.5% | 0.00% | 0.0% |
| Q3 2023 | $1,891,179 | -13.7% | 240,608 | -2.5% | 0.00% | 0.0% |
| Q2 2023 | $2,190,794 | 0.0% | 246,711 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,190,794 | -18.7% | 246,711 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $2,695,547 | -99.9% | 245,496 | +6.5% | 0.00% | -50.0% |
| Q3 2022 | $3,004,614,000 | -2.9% | 230,592 | -5.6% | 0.00% | 0.0% |
| Q2 2022 | $3,095,344,000 | -12.8% | 244,305 | -3.5% | 0.00% | 0.0% |
| Q1 2022 | $3,548,340,000 | -56.1% | 253,272 | -9.2% | 0.00% | -33.3% |
| Q4 2021 | $8,073,866,000 | -5.8% | 278,890 | -2.5% | 0.00% | -25.0% |
| Q3 2021 | $8,571,525,000 | +13.0% | 286,099 | +0.1% | 0.00% | +33.3% |
| Q2 2021 | $7,584,396,000 | – | 285,880 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |